Elizabeth Dees is an Oncology physician affiliated with University of North Carolina at Chapel Hill. OpenAlex indexes 409 publications with 15,742 citations (h-index 46); ClinicalTrials.gov lists 8 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
101 Manning Dr
Chapel Hill, NC 275990001
Telephone
919-966-4996Registry record last updated 8 Jul 2007.
Clinical trials
- A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer
Sponsor: National Cancer Institute (NCI)
- Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer
Sponsor: UNC Lineberger Comprehensive Cancer Center
- Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors
Sponsor: NewLink Genetics Corporation
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- SANOFI-AVENTIS U.S. LLCProgram year20222 payments$10,356openpaymentsdata.cms.gov ↗
- SANOFI-AVENTIS U.S. LLCProgram year20211 payment
- Gilead Sciences, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
6 NIH research awards on record, funded 2002–2025 per NIH RePORTER. The latest:
- Clinical Protocol and Data Management (Core 018)
Univ of North Carolina Chapel Hill
FY2020$689,776P30CA016086 - EARLY PHASE CLINICAL RESEARCH SUPPORT (Core 020)
Univ of North Carolina Chapel Hill
FY2020$287,368P30CA016086
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A phase 1, first-in-human (FIH) study of the anti-HER2 CAR macrophage CT-0508 in subjects with HER2 overexpressing solid tumors.
Journal of Clinical Oncology
2022 - Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial
JNCI Journal of the National Cancer Institute
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Lisa Carey, MD
University of North Carolina at Chapel Hill
Robert Sandler, MD
University of North Carolina at Chapel Hill
Diana Perkins, MD
University of North Carolina at Chapel Hill
Hyman Muss, MD
University of North Carolina at Chapel Hill
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”